Testing a new ultrasound device for fatty liver in adults with MASLD
Tests a portable ultrasound device to measure liver fat in adults with MASLD.
Plain-language title generated from the registry record
Registry title: Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients
Key facts
- Where
- Angers, Clichy, and Paris, FranceSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06661655, who can take part
Where in France
- University Hospital AngersAngers, FranceTaking people
- Beaujon University HospitalClichy, FranceTaking people
- Pitié-Salpêtrière University HospitalParis, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- E-Scopics
- Trial code
- NCT06661655
- Record updated
- 15 August 2025
- Original description
The objective of the study is to evaluate an ultraportable ultrasound device, Hepatoscope, for the non-invasive assessment of hepatic steatosis in patients with metabolic-dysfunction associated liver diseases (MASLD), by comparing its measurements with current diagnostic modalities, such as MRI-PDFF.Read full original descriptionShow less
Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients
The objective of the study is to evaluate an ultraportable ultrasound device, Hepatoscope, for the non-invasive assessment of hepatic steatosis in patients with metabolic-dysfunction associated liver diseases (MASLD), by comparing its measurements with current diagnostic modalities, such as MRI-PDFF.
Inclusion: Adult patient below 80 yo; Patients with MASLD/MASH recruited in interventional trials requiring MRI PDFF +/- MRE per interventional protocol, OR; Patients with MASLD/MASH recruited in prospective cohorts requiring MRI PDFF +/- MRE per interventional protocol, OR; Patients referred to MRI-PDFF or MRE; Patients who consented in written to participate in the study; Patients with ongoing social security coverage.
Exclusion: Patient with active implants,; Patient with a history of decompensated cirrhosis,; Patient with a history of hepatocellular carcinoma,; Patient presenting with another know liver disease; Patient in their minority (less than 18 yo) or older than 80 yo,; Patient presenting with a wound where the Hepatoscope exam shall be performed (abdominal right upper quadrant); Adult patient under tutorship, or unable to express informed consent,; Pregnant or breast-feeding; Person deprived from their liberty; Patient hospitalized without providing consent or in case of an emergency.